Company Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
The company’s preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions.
The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015.
Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
| Country | United States |
| Founded | 2009 |
| IPO Date | Oct 4, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 111 |
| CEO | Dr. Victor Perlroth M.D. |
Contact Details
Address: 1200 Page Mill Rd Palo Alto, California 94304 United States | |
| Phone | 650-281-0850 |
| Website | kodiak.com |
Stock Details
| Ticker Symbol | KOD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001468748 |
| CUSIP Number | 50015M109 |
| ISIN Number | US50015M1099 |
| Employer ID | 27-0476525 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Victor Perlroth M.D. | Co-Founder, Chairman, Chief Executive Officer and President |
| John A. Borgeson CPA, M.B.A. | Senior Vice President, Chief Financial Officer and Secretary |
| Dr. Michael S. Louie Ph.D. | Senior Vice President of Digital Transformation and Chief Information Officer |
| Dr. Hong Liang | Senior Vice President of Discovery Medicine |
| Dr. Stephen Raillard Ph.D. | Senior Vice President of Chemical Development and Manufacturing |
| Almas Qudrat M.Sc. | Senior Vice President of Quality Operations |
| Dr. J. Pablo Velazquez-Martin M.D. | Senior Vice President of Clinical Research and Development |
| Tracy Chien | Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 6, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | 8-K | Current Report |
| Apr 23, 2024 | ARS | Filing |
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |